Digital biomarkers market to witness significant growth due to growing adoption of digital healthcare solutions and rising prevalence of chronic diseases, like cardiovascular diseases, diabetes, cancer and neurological disorders.

Market Research Future (MRFR) has published a cooked research report on the “Global Digital Biomarkers Market” that contains information from 2018 to 2032. 

Market Highlights

The global Digital Biomarkers market is accounted to register a CAGR of 22.60% during the forecast period and is estimated to reach USD 19.39 billion by 2032.

The rising chronic disease burden, like diabetes, cardiovascular diseases, cancer and neurological disorders are becoming increasingly prevalent worldwide. Factors like aging populations, unhealthy lifestyles, and environmental factors contribute to the growing burden of these diseases. Chronic diseases often require continuous monitoring to manage symptoms, track disease progression and adjust treatment plans. Digital biomarkers, collected through wearable devices, mobile apps and digital tools, enable continuous and real-time monitoring, early detection, and personalized management. Further, the pharmaceutical companies and research increasingly rely on digital biomarkers to optimize clinical trials and drug development processes.

Key Players

MRFR recognizes the following companies as the key players in the global Digital Biomarkers market— ActiGraph LLC; AliveCor Inc.; Koneksa; Altoida Inc.; Amgen Inc.; Biogen Inc.; Empatica Inc.; Vivo Sense; IXICO plc; Adherium Limited; Neurotrack Technologies, Inc.; Aural Analytic; Huma; Sonde Health, Inc.

Segment Analysis

The global Digital Biomarkers market has been segmented based on type, clinical practice and end user.

On the basis of type, the market is segmented into Wearable, Mobile Based Applications, Sensors and Others. The wearable segment was attributed to holding the largest market share in 2022, as these wearables provides continuous data collection.

Based on clinical practice, the global Digital Biomarkers market has been segmented into Diagnostic Digital Biomarkers, Monitoring Digital Biomarkers, Predictive and Prognostic Digital Biomarkers and Others. The diagnostic digital biomarkers segment was expected to hold the largest market share in 2022, as they can be used to identify specific patterns in digital health data.

On the basis of end user, the market is segmented into Healthcare Companies, Healthcare Providers, Payers and Others. The healthcare companies segment was attributed to holding the largest market share in 2022, due to the growing adoption of new digital biomarkers.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Digital Biomarkers Market Research Report

Regional Analysis

The global Digital Biomarkers market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Digital Biomarkers market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Digital Biomarkers market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Digital Biomarkers market comprises of Middle East, Africa, and Latin America.

The largest market share for Digital Biomarkers was maintained by the North American regional sector. The region boasts a highly developed and advanced healthcare infrastructure, including state-of-the-art hospitals, research institutions and healthcare facilities. It is home to many leading pharmaceutical and biotechnology companies. It also has a thriving ecosystem of academic and research institutions and innovative startups, dedicated to healthcare technology and biotechnology, fostering a culture of innovation and collaboration, driving advancements in digital biomarker development.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for Digital Biomarkers is driven by rising awareness and education about the benefits of digital biomarkers. The region has an increasing number of aging population and rising cases of chronic diseases. The government is actively promoting the adoption of digital health solutions as part of their healthcare strategies.

Additionally, Asia Pacific is predicted to develop the fastest throughout the projection period because to the rising prevalence of chronic illnesses, government measures to promote digital health and telemedicine, increased technology breakthroughs, and an ageing population. Further, the region is attracting investments from both domestic and international companies in the healthcare technology and digital health sectors, fueling the innovation and driving the development and adoption of digital biomarkers.

Furthermore, the rest of the world's Digital Biomarkers market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the growing chronic disease burden and aging population and growing investment in digital health and technology startups in this region. The practicality of the technology in the industry, increased investor interest, and government assistance are all contributing reasons to the market development.

Key Findings of the Study

• The global Digital Biomarkers market is expected to reach USD 19.39 billion by 2032, at a CAGR of 22.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the increasing government initiatives, technological advancements and growing patient engagement in digital health.


• Based on type, the wearables segment was attributed to holding the largest market in 2022, with an approximate market share of 40%.


• ActiGraph LLC; AliveCor Inc.; Koneksa; Altoida Inc.; Amgen Inc.; Biogen Inc.; Empatica Inc.; Vivo Sense; IXICO plc; Adherium Limited; Neurotrack Technologies, Inc.; Aural Analytic; Huma; Sonde Health, Inc.